BNET Industries
Eli Lilly & Co. (LLY) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $18.6B
- Profit
- Dec 31 2007
- $2.9B
- Market Cap
- Jul 17 2008
- $55.0B
Latest News and Analysis
Will Lilly's Survey Have the Desired Effect on Cialis?
Mike Huckman submits: More than ten years after Pfizer PFE brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctors. The study, paid for by Clialis-maker Eli...
Dividend Growth Stocks: A Salve for the Bear's Bite
Alan Brochstein, CFA submits: I have frequently written about high quality dividend growth stocks, most recently about two months ago. I seem to receive very favorable responses to those articles, but after that one, I was told by one reader than my work was "laughable." He bragged about...
Eli Lilly: Good Dividend but Is the Stock Worth the Risk?
Dividends4Life submits: Linked here is a PDF copy of my analysis of Eli Lilly and Co. (alt.1, alt.2). Below are some highlights from the above linked analysis: Company Description: Eli Lilly and Company LLY discovers, develops, manufactures and sells prescription drugs that offers a wide range of treatments...
Merck, Lilly and Pfizer Get Behind Enlight
Derek Lowe submits: Here's an interesting idea: Merck MRK, Lilly LLY, and Pfizer PFE are bankrolling a startup company to look for new technologies for drug development. Enlight Biosciences will focus on the biggest bottlenecks and risk points in the process, including new imaging techniques for preclinical and clinical...
Pfizer, Merck and Lilly Partner to Get "Enlightened"
Mike Huckman submits: Big pharma makes strange bedfellows. Pfizer PFE, Merck MRK, and Eli Lilly LLY announced yesterday morning that they've launched a joint venture of sorts called, "Enlight Biosciences". They're doing it with the help of the Boston-based VC ("Venture Creation," the website says, not "Venture Capital") firm...
Big Pharma Stocks: Real Rally or Just a One Day Wonder?
Mike Huckman submits: One day does not a full-fledged sector rotation make, but Tuesday the big pharma stocks put on a show and in the early going on Wednesday the curtain hadn't fallen. Pfizer PFE even broke above 18 bucks! by Mike Huckman
FDA Delivers One-Two Punch to Merck & Eli Lilly
Mike Huckman submits: For the second time in three days, the Food and Drug Administration has delayed making a decision on drugs that it had put on a fast track. First, the agency put off a ruling on Lilly's LLY bloodthinner Effient, and then yesterday morning, Merck MRK announced...
Troubles With Lilly's Effient Empire
Mike Huckman submits: Tree huggers (just a colloquialism, not a dig) will be glad to know that biopharmaceutical companies submit their Food and Drug Administration filings for drug approval electronically these days. Dr. Tony Ware, the head of Eli Lilly's LLY cardiovascular unit, says his people tell him that...
Tuesday Options Update: TSO, QID, XRT, LLY, EK, BAC, NTAP
Tesoro TSO – Call volume and volatility in oil refiner Tesoro shot sharply higher, one day after Bloomberg news revealed that insider buying in refinery stock had reached a 8-year high on speculation of an imminent pullback in oil prices – and perhaps goaded on by continuing revelations on Capitol...
What's Happening in Research and Development?
Joe Ponzio submits: Today's research and development [R&D] is tomorrow's new product or process. The other day we (or more specifically, Phil Fisher) asked, "Does the management have a determination to continue to develop products or processes that will still further increase total sales potentials when the growth potentials...
Pfizer Makes a Deal, Wyeth and Elan Release Alzheimer's Drug Results
Mike Huckman submits: Last week, Pfizer PFE made a major announcement regarding the world's top-selling statin, Lipitor. Pfizer struck a deal with the Indian generic drugmaker Ranbaxy to ward off the threat of generic competition for Lipitor until late 2011. I know there were a lot of market pressures...
Potential BioMS: Successful Drug Trials but Risk Still Exists
FP Trading Desk submits: A successful phase II trial of BioMS Medical Corp.'s (BOMSF.PK) lead compound dirucotide for the treatment of Multiple Sclerosis would undoubtedly give a boost to the biotech share price, but with results not expected to start rolling out until the first quarter of 2009, investors...
Mid-Year Picks and Pans From Barron's Roundtable Part III
Barron's magazine returns to its 11 Roundtable participants, who weigh-in with their mid-year thoughts, and updated stock picks. see part I and part IIFelix Zulauf He sees 3-4 years of market choppiness ahead. Financials and consumers will remain weak; energy and agriculture stocks will keep rising....
In GLP-1 Wars, Novo & Others Knock at Amylin?s Door; Find Amylin Moved to Pricier Digs
Dr. Fredric Cohen submits: Taspoglutide advancement announcement by Fredric Cohen, M.D.
The 20 Highest Yielding Dividend Aristocrats
Dobromir Stoyanov submits: In today’s low interest rate environment, retirees are having a hard time finding tax efficient income opportunities, worthy of their money, which would help them enjoy their post-working years. A great idea for income seeking investors is investing in stocks that pay good yields and have consistent...
Is Lilly and Amylin's Byetta Better?
Mike Huckman submits: Shares of Amylin AMLN ambled higher yesterday after two destructive trading days. First, last Friday, Novo Nordisk NVO put out a press release saying preliminary data show its drug works better than Byetta. And then, Monday an analyst downgraded the stock just ahead of the company's...
ADA's 68th Scientific Sessions: A New Look at Insulin Therapy
R.J Steffens submits: The American Diabetes Association's 68th Scientific Sessions kicked off in San Francisco on June 6th and ends June 10th. Large pharma dominates the exhibition and use the venue to present their latest study results in an effort to orientate health care professionals on the products they may...
Analyst Notes: Lilly Gets A Lift, Pfizer Goes Pfft
Mike Huckman submits: Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's PFE oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold. But Eli Lilly LLY is the biggest dollar and percentage...
Eli Lilly & Co. Q1 2008 Earnings Call Transcript
Eli Lilly & Co. Q1 2008 Earnings Call Transcript
A Billion-dollar Email 'Whoops!'
The day was probably same as any other day for a Philadelphia lawyer who was working on a settlement case between big pharmaceutical player Eli Lilly and the U.S. Government. Eli Lilly was in talks with the federal government over marketing improprieties related to their bipolar drug, Zyprexa. The...
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Healthcare (12 results)
- Pfizer Inc. (9 results)
- Earnings (5 results)
- Seeking Alpha (5 results)
- Financial Accounting (5 results)
- Finance (5 results)
- Biotech (5 results)
- Call Transcript (5 results)
- US Market (4 results)
- Amylin Pharmaceuticals Inc. (4 results)
- Merck & Co. Inc. (4 results)
- Sanofi-Aventis (3 results)
- Online Communications (3 results)
- E-mail (3 results)
- Bristol-Myers Squibb Co. (3 results)
- NUVO Network Management Inc. (3 results)
- GlaxoSmithKline Plc. (3 results)
- Incorporated: 1901
- CEO: Dr. John C. Lechleiter Ph.D.
Eli Lilly is engaged primarily in the discovery, development, manufacture, and sale of pharmaceutical products. Co.'s principal products are: Neurosciences products, which includes Zyprexa®, Strattera®, Prozac®, Cymbalta® and Symbyax®; Endocrinology products, including Humalog®, Humalog Mix 75/25®, and Humalog Mix 50/50™, Humulin®, Actos®, Byetta®, Evista®, Humatrope®, and Forteo®; Oncology products, including Gemzar® and Alimta®; Cardiovascular products, including Cialis®, ReoPro® and Xigris®; and other pharmaceutical products, including Vancocin® and Ceclor® . Co. also has an animal health segment.
Key Competitors
Eli Lilly & Co. Company Info
Board of Directors
Mr. Sidney Taurel
Chairman
Mr. J. Erik Fyrwald
Ms. Ellen R. Marram
Mr. Michael L. Eskew
Dr. John C. Lechleiter Ph.D.
Sir Winfried Bischoff
Mr. J. Michael Cook
Dr. Franklyn G. Prendergast Ph.D.
Ms. Kathi P. Seifert
Dr. Alfred G. Gilman Ph.D.
Dr. Karen N. Horn Ph.D.
Dr. Martin S. Feldstein Ph.D.
Contact Information
Lilly Corporate Center
Indianapolis, IN
317 276 2000
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
